Antimicrobial peptides for the treatment of pulmonary tuberculosis, allies or foes?

Author(s): Bruno Rivas-Santiago*, Flor Torres-Juarez.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 10 , 2018

Become EABM
Become Reviewer

Abstract:

Tuberculosis is an ancient disease that has become a serious public health issue in recent years, although increasing incidence has been controlled, deaths caused by Mycobacterium tuberculosis have been accentuated due to the emerging of multi-drug resistant strains and the comorbidity with diabetes mellitus and HIV. This situation is threatening the goals of World Health Organization (WHO) to eradicate tuberculosis in 2035. WHO has called for the creation of new drugs as an alternative for the treatment of pulmonary tuberculosis, among the plausible molecules that can be used are the Antimicrobial Peptides (AMPs). These peptides have demonstrated remarkable efficacy to kill mycobacteria in vitro and in vivo in experimental models, nevertheless, these peptides not only have antimicrobial activity but also have a wide variety of functions such as angiogenesis, wound healing, immunomodulation and other well-described roles into the human physiology. Therapeutic strategies for tuberculosis using AMPs must be well thought prior to their clinical use; evaluating comorbidities, family history and risk factors to other diseases, since the wide function of AMPs, they could lead to collateral undesirable effects.

Keywords: Anti-inflammatory, antimicrobial peptides, immunomodulation, treatment, pro-inflammatory, tuberculosis.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 10
Year: 2018
Page: [1138 - 1147]
Pages: 10
DOI: 10.2174/1381612824666180327162357
Price: $58

Article Metrics

PDF: 15
HTML: 4
EPUB: 1
PRC: 1